Global Personalized Medicine Industry Examined by Kelly Scientific Publications in New Study Available at

30 Jul 2013 • by Natalie Aster

LONDON – Worldwide, the personalized medicine and associated companion diagnostic market have huge opportunities for growth. The industry is predicted to revolutionize the healthcare system and improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics.

The key concerns of the personalized medicine market today include the lack of regulatory policy and legislation in the United States and Europe; reimbursement schemes and payers’ concerns; transition of investigational diagnostic assays and therapeutics to clinical practice; and direct to consumer (DTC) test kits and implications for the public.

New topical research study “Personalized Medicine and Companion Diagnostic Market Q2 2013 - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment” drawn up by Kelly Scientific Publications provides an in-depth understanding of the global personalized medicine market and its impact on the healthcare system.

The report describes the current technologies that are propelling the personalized medicine and companion diagnostic market; examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today; discusses current developments in personalized medicine and the pharmacogenomics revolution; analyses emerging trends that appear in key markets such as the US, UK, Germany and France. Market figures of both the overall personalized medicine market and its sub-markets are revealed. The study also provides a comprehensive financial and product review of key players in the personalized medicine field. Strategic drivers and restraints of the market are highlighted, and market opportunities and challenges are identified. To give a forthcoming perspective of the evolving industry, the research also presents forecast projections and future growth rates.

Key pharmacos discussed include: 23andMe, Affymetrix, Astex Pharmaceuticals, Atossa Genetics, CuraGen, Celera Corporation (Quest Diagnostics), Celldex Therapeutics, deCode Genetics (Amgen), Illumina, Genelex, Myriad, Nodality and Qiagen.

Report Details:

Personalized Medicine and Companion Diagnostic Market Q2 2013- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment
Published: July, 2013
Pages: 205
Price: US$ 3,630.00

More new market research studies by the publisher can be found at Kelly Scientific Publications page.


MarketPublishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970